Introduction
The idea of promoting evidence based medicine, understood as practicing according to the best evidence based on exhaustive and systematic reviews of all available data, is very convincing and difficult to contest rationally. 1 This certainly does not mean that the exact type of evidence to take into consideration is indisputable. Thus, Maynard [2] recently accused leading spokesmen for the evidence based medicine 'movement' of completely ignoring treatment costs by recommending that treatment decisions be made merely on the basis of efficacy data [3] .
Concerning the establishment of the best current clinical evidence, many years of research and discussion have gradually developed into a 'science of systematic reviews', with at least broad agreement about the principles to follow when collecting, evaluating and summarizing evidence. With respect to establishing evidence on efficiency, i.e., the relation between clinical outcomes and the associated costs of treatment, the question about systematic reviews of evidence from primary studies is only just beginning to arise [4] [5] [6] [7] [8] [9] [10] .
This article deals with some of the issues involved in systematic reviews of economic evaluations in health care. It is argued that the principal concern should be with the problems involved in carrying out secondary analyses, ie transferring the results of studies to other health care settings than the one in which the primary evaluation has been performed.
A few fundamentals of economic evaluations in health care
An economic evaluation of a treatment choice is a comparison of at least two different treatments of a particular disease with the same or similar objective(s), such as increasing the patients' quality adjusted survival. Both the costs and the clinical outcomes of the alternatives are determined and given equal importance. A principal task of any economic evaluation is to ensure that the evaluated alternatives are all investigated and valuated in a systematic, consistent, and comprehensive way.
Cost calculations consist of two quite distinct parts. One is the identification and quantification of all the various types of resources that are used for performing the treatments, including any derived impacts such as adverse effects that require further treatment. The other part, and usually the most difficult, is to find a consistent set of unit costs (prices) for all the resources concerned. Total costs are subsequently found by multiplying, for each type of resource identified, the quantity consumed by an appropriate unit price and summing over all the resources consumed.
The unit prices used for cost calculations may derive from several sources, including official tariffs and charges, routine hospital accounting data or detailed cost determination efforts carried out for the specific purpose of the study. The relevant set of unit prices will depend on the perspective chosen for the study (e.g., the hospital, the health insurance system, society at large), and this choice may make a considerable difference. More importantly for the present context, the set of unit prices will pertain to a particular social context and time period, so any economic evaluation will inevitably be tied to a specific health care setting and point in time. Thus, the question about the external validity of results becomes crucial for anybody wishing to use a study for informing decisions in another context than where the study has been performed.
Despite the fact that the central objective of applying the methods of economic evaluation to health care interventions is to provide evidence on the relation between clinical outcomes and the associated costs, these two aspects have conventionally been examined quite separately. The relation between costs and clinical outcomes have been depicted by the construction of more or less complex and sophisticated models, and data to feed these have usually been taken from many diverse and unrelated sources. Most often, clinical outcome data and frequencies of adverse events are derived from a randomized controlled trial involving the treatments included in the evaluation. Resource utilization data may come from many sources. Frequently, they derive from an examination of patient charts in a particular treatment institution (see Neymark [11] ).
More recently, the idea that economic evaluations should preferably be integrated prospectively in randomized controlled trials, so that clinical and cost data are collected for the same sample of patients, has become widespread. This integration of economic evaluation in clinical trials has raised a large number of still unresolved methodological and statistical issues [12, 13] . Despite these, an increasing number of economic assessments will most likely be based on clinical and cost data collected within the same trial, often supplemented with some modeling, e.g., for extrapolations outside the follow-up period of the trial.
Objectives of systematic reviews of scientific evidence
The essential objective of carrying out a systematic review of any particular clinical problem is to summarize the available evidence in order to inform decisions about the best way of managing a group of patients. A fundamental idea behind recent efforts at developing a science of systematic reviews is to avoid the subjectivism inherent in the traditional form of review. The notion is that objective knowledge based on the best available evidence may only be obtained by adhering to pre-established procedures for the collection and evaluation of information. This should ensure that independent reviewers would reach identical conclusions.
One important step in making reviews more objective is to combine or pool their data statistically in a socalled meta-analysis. Ideally, a meta-analysis based on individual patient data from all randomized controlled trials of a particular problem can combine the outcome estimates of the individual studies into a single best estimate with an associated confidence interval [14, 15] .
Would it be feasible, after having retrieved all published as well as non-published, economic evaluations of a particular clinical problem, to carry out a meta-analysis of these and combine their results to obtain a single best estimate of the relation between clinical outcomes and costs? Or, should the objectives of carrying out systematic reviews be reconsidered, when economic evaluations are concerned?
Feasibility of meta-analysis of economic evaluations
In clinical trials and meta-analyses of these, whether a fixed effect or a random effect model is hypothesized, it is a fundamental assumption that the outcomes observed are simply due to the biological effects of the treatments concerned and that they are independent of the specific health care settings in which they have been carried out. This is a basic premise for the notion of adding evidence from several trials in order to obtain more precise estimates of the outcomes of interest.
While this assumption is rarely questioned in clinical studies, it is obviously untenable with regard to cost calculations, the complementary part of economic evaluations. The pertinent unit prices vary from one health care setting to another, and the resulting costs may thus vary considerably between two settings, even if resource utilization should be entirely identical [16] . Differences in unit costs are most obvious between countries, but even within individual countries there may be substantial differences in factor prices, particularly in salaries and benefits. Thus, it is not uncommon to find that the remuneration of a certain category of labor, e.g., physicians with a particular degree of specialization and experience, may vary by perhaps 15%-20% within the same country.
When considering comparisons of costs between countries it should also be appreciated that not only absolute price differences influence the results. It is likely that differences in the relative prices and in the institutional and financial settings within which the decision makers (e.g., physicians) are acting, may imply that the entire management of patients may be very different. A good example of this is a study conducted by Bredeson et al. [17] of the costs of peripheral blood stem-cell transplantations. In trying to compare their findings to those of a related study [18] , Bredeson et al. concluded that the direction of the overall results was similar despite numerous important differences in patient management, eg in the criteria for hospital admission and discharge, for stays in intensive care units, etc. However, if economic evaluations are to be useful for decision making and priority setting, exact quantitative results are required. Just knowing the direction of results will not suffice.
In comparing the costs of a health care intervention performed in two or several different countries, it is important to be aware of the possible confounding of differences in resource use with differences in absolute and relative unit prices of the resources concerned. If the objective in comparing various sites is to determine the relative costs in terms of the real quantities of resources used, the best thing to do is probably to calculate the costs at both sites by using the unit costs of just one of the sites. By this means one may construct an index, as a summary measure of the real resource consumption at each site. This will enable comparisons, by eliminating the complexities due to the large number of resource items usually involved, without the confounding influence of differences in absolute and relative prices.
Another complication is the quality of diagnostic and therapeutic procedures which may influence costs significantly. This engenders important uncertainty, as it is difficult in a cost calculation to determine, which factors decide the quality. Of significance may be the competence and experience of a clinician or a whole clinical team, the quality of equipment and the entire structure of the health care setting. In multinational studies, you cannot be certain that personnel with the same designation also have the same qualifications and competences, making comparisons in physical resource units uncertain.
In summary, there is no economic foundation for supposing that the costs of a particular health care intervention carried out in different countries and health care settings should converge towards a common value, which might then be estimated more precisely by pooling data from several independent cost calculations. As long as countries differ in their costs of medical and non-medical services, institutional health care framework and treatment patterns, no convergence of costs should be expected.
Despite this, the assumption of cost convergence is very common, at least implicitly. Thus, in the discussion part of most economic evaluations in health care, there are references to the results of other studies of similar interventions carried out in other settings. The suggested explanations for observed differences in the results rarely refer to the simple fact of differences in factor prices, and conversely, similarity of the results is usually taken as a confirmation of the plausibility of the calculations presented. The superficiality of such cost comparisons is evident, given the usually important differences between the studies from which they derive.
The rationale for carrying out systematic reviews, or what should perhaps rather be called secondary analyses, of economic evaluations derives from other considerations. For example, systematic reviews might be used to assess the relation between costs and outcomes of the therapeutic alternatives in different settings and to investigate possible reasons for the divergencies likely to be observed. The principal purpose, though, is to investigate the possibilities for transferring results of studies carried out elsewhere to any particular health care setting. This is because drawing upon experiences gained elsewhere is an important alternative to the prohibitively costly and time consuming option of carrying out local economic evaluation of all the treatment choices in which an economic assessment is indicated. In the following section, the steps involved in performing secondary analyses of economic evaluations are enumerated and discussed.
Performing secondary analyses of economic evaluations
The considerations to follow are very general and concern the situation, in which the aim of conducting a secondary analysis is formulated rather vaguely, as examining the impact on costs and clinical outcomes of the various treatment options for a particular patient population. Alternatively, the aim of a secondary analysis may be to examine the transferability to a particular local health care setting of the results of a specific economic evaluation carried out elsewhere. Many of the steps mentioned may in that instance be leaped over.
Specify the decision problem and the decision context
Both the clinical decision problem and the decision context should be clearly defined from the outset, as they determine the search for relevant studies and the appraisal of the studies retrieved. In general, it may be an advantage to define both the clinical problem and the health care setting rather broadly and subsequently impose additional criteria. An example of a very broad search is found in Fervers et al. [19] , who looked for economic evaluations of adjuvant treatment for breast cancer and aimed to assess their transferability to the French health care system. 2 
Identify and retrieve all relevant studies
The objective of trying to find and examine all relevant studies is primarily to ensure that no important factors are overlooked and to gain an insight into the possible impact of the various factors in the different health care settings in which the studies have been performed. For instance, variations in financing systems could produce differences in the clinicians' incentives for managing their patients in a particular way, e.g., admitting them to hospital or treating them on a day clinic basis. As with clinical meta-analyses there may be a problem with publication bias [9] , and even published studies may sometimes be difficult to find by using the usual bibliographic databases. A manual search of the reference lists of all retrieved papers will normally increase the yield considerably and must be considered mandatory. As the aim of the review is not to result in a single best estimate of the relation between costs and outcomes, a complete retrieval of all studies performed is arguably less important than for clinical meta-analyses aiming at obtaining a best estimate of efficacy.
Further criteria for selection of primary studies
After the initial screening of the literature based on broad search criteria, the relevance of the retrieved studies for the local health care setting must be critically assessed by asking a number of questions. Studies not fulfilling these additional criteria will in general be discarded as not pertinent for the decision problems posed in the health care setting concerned.
The most obvious criteria are the initial clinical questions, such as: 1) Is the patient population to which the treatments were given the same as the patients that we are focusing on? 2) Are the investigational treatments (about to be) used in the local setting? 3) Is the comparator treatment used in the local setting? Other questions might turn on the relevance of the clinical endpoint(s) of the studies for the local setting, and whether any value judgments (such as quality of life valuations) are considered applicable.
More difficult to assess, but potentially of decisive importance for the transferability of the results, are questions concerned with the organizational framework within which the studies have taken place and the ensuing incentives for health care providers and institutions. These factors may have considerable influence on the patterns of resource utilization, but the differential impact of variations in institutional framework is difficult to assess precisely. Studies not fulfilling the clinical criteria may easily be discarded as of no interest for the secondary economic analysis, while studies from settings with a different institutional framework may still be interesting and in need of careful examination.
Assessment of the quality of the studies retrieved
A sine qua non for considering the possibility of transferring the results of a study to other than the original setting is obviously that the study is of good quality and that the results are considered valid and reliable. There have been many attempts at denning a set of quality criteria to be used in appraising studies, and many such appraisals have been carried out and published over the years. A recent set of criteria, which probably commands widespread agreement, was published by Drummond and Jefferson [20] .
The present paper is not the appropriate place for a further presentation and discussion of the suggested criteria, which are in line with other criteria that have previously been used for assessments of the published literature. The common conclusion of such assessments [21] is that the observance of the quality criteria is quite poor, and that any tendencies for improvement over time are barely visible. The finding of [21] that only 4% of the studies examined fulfilled all the criteria and that the median rate of observance was only 50% must necessarily lead to scepticism concerning the entire idea of transferring study results. However, such quality assessments are usually crude, as they just count the number of criteria fulfilled without judging their relative importance for the overall quality of a study.
A few of the criteria proposed by [20] are of particular relevance for the possibility of transferring the results to other health care settings. The first of these is that the study question should be phrased in a way that considers both costs and outcomes and with a clear statement of the primary outcome measure for the economic evaluation (e.g., QALYs). This is an obvious requirement, although far from generally observed, but it is also important for the interpretability of the results after transferring them, as there may for instance be local data available on threshold values acceptable for costs per QALY. The second is that the viewpoint of the study should be clearly stated, as this has decisive importance for the cost items included and for the unit cost figures used for valuation of costs. This is another basic requirement, which is all too often not respected [11] . In relation to transferability of results to other health care settings it is important to notice that this particular question needs careful examination because of the differences among countries in the institutional structures and health care financing systems.
The most important requirements posed by [20] are probably that the interventions compared should be described in sufficient detail that the reader is able to assesss their relevance for his own setting and that the quantities of resources consumed should be reported separately from the unit prices used for cost valuation. If this fundamental principle is observed, it will be possible for interested readers to perform an initial rough recalculation by inserting local unit prices and multiplying by the quantities used in the original study.
Further, any kind of modelling used should be transparent and explicit and enough details should be given to allow any reader to replicate the analysis. A major problem with published studies is that the effectiveness data are often taken from a particular trial, without sufficient information given on the whole body of evidence available. Alternatively, the authors have conducted an ad hoc synthesis of evidence, often mixing evidence of various quality, 3 e.g., from case series and RCTs. 4 In general, the major emphasis should be on making study reports entirely transparent, which is certainly possible and not a lofty ideal. Further, data should primarily be presented in a disaggregated form before any presentation of summary measures such as costeffectiveness ratios. Reporting in journal articles may have to be limited to a number of main cost items, but study authors should be obliged to make a full report available upon request. 5 
Adaptation to a particular health care setting
Assessment of the external validity of evaluation studies is normally difficult and the general evaluation literature [23] contains little beyond stating common sensical observations. As the very attempt at transferring the results of a study to other settings than the original necessarily implies that a modeling effort is involved, one point of departure might be to define the characteristics of a good model. These are discussed in Neymark et al. [13] , but, once again, most of the observations must admittedly be characterized as bordering on the obvious. The fundamental importance of clearly stating all assumptions, describing sources of frequencies and motivating choices made when several options are available is repeatedly stressed, however. Provided that the requirement of full transparency is observed, it is hardly possible on a general level to delimit the kind of evidence that should be considered admissible for assessing the transferability of a particular study to a specific local health care setting.
Such assessments must accordingly be performed from case to case and will inevitably be somewhat ad hoc in character. Transferability of study findings is most obvious in cases, where it is considered that only the unit prices used for cost calculations must be substituted by locally valid unit prices. But, even in this case, the assess-ment that only unit prices need to be changed will often be difficult to justify in any detail because of lack of pertinent data.
An interesting example of the considerations entailed in an attempt at transferring results of an economic evaluation to other settings is related by Todd [24] . The West of Scotland Coronary Prevention Study (WOSCOPS), which investigated the cost effectiveness of pravastatin prophylaxis of cardiovascular disease, was adapted to the Canadian setting by one of the developers of the WOSCOPS economic model. This adaptation involved much more than adjustments of unit cost figures, including substitution with Canadian data on resource use. The clinical efficacy of pravastatin prophylaxis was assumed to be exactly the same, while survival projections and baseline risk values were changed based on available secondary data. If Canadian values were lacking for variables (such as compliance), which according to the study authors were highly unlikely to be identical, they chose to use values from the original Scottish study while allowing for later revisions in case new data should become available. Another example of an attempt to corrrect for intercountry differences in patient management is provided by Menzin et al. [25] .
One may disagree with the assumptions made in this study or the choices made between various data sources. But a fundamental purpose of requiring full transparency in modeling is precisely to allow rational diasgreement and revisions upon the appearance of new data. This observation was made already by Weinstein et al. in their classic book [26] on medical decision making.
Conclusions
The well-known intercountry differences in the costs of medical and non-medical goods and services should preclude any expectation of convergence of the costs of specific health care interventions. Consequently, as economic evaluations aim to determine the relation between clinical outcomes, assumed universally valid, and costs, which must necessarily depend on the specific health care setting and time point chosen, the results will certainly differ between different settings. The idea of carrying out meta-analyses of similar economic evaluations carried out in different settings in order to obtain more precise estimates of the relation between costs and outcomes is thus rather meaningless. Despite this, it is quite common in the economic evaluation literature to find reasoning implying assumptions of cost equivalence or convergence.
The primary purpose of conducting systematic reviews of economic evaluations of particular health care interventions should be to enhance the likelihood that all the factors of relevance for the transferability of the results to a particular local health care setting are taken into account. The local applicability of the findings of any particular economic evaluation must then be assessed on the basis of the available local data for the important variables. In addition to unit cost figures, these data may comprise everything influencing the costs, such as patterns of patient management and resource use, patient compliance and baseline risks, etc. It is difficult to formulate general guidelines for the admissibility of various types of evidence and these must be assessed from case to case. [19], 17 were excluded by a first quality appraisal, eg because it was not possible to identify the viewpoint of the analysis. Of the nine studies left, several were considered not relevant for the French health care system, because (one of) the comparators evaluated are not used in (more than a few) French cancer centers and university hospitals. 3. According to the rating of the quality of evidence formulated by Cook et al. [22] . 4. Many examples of this practice are provided in [11] , which also discusses a few noticeable examples of studies giving a careful discussion of the available evidence and providing a reasoned choice. 5. Many analysts trying to carry out meta-analyses based on individual patient data will have experienced some problems in retrieving data from all identified studies. Some journals have initiated a policy of making it a condition for publication that the empirical data are made publicly available.
